List of Inomax drug patents

Inomax is owned by Mallinckrodt Hosp.

Inomax contains Nitric Oxide.

Inomax has a total of 30 drug patents out of which 0 drug patents have expired.

Inomax was authorised for market use on 23 December, 1999.

Inomax is available in gas;inhalation dosage forms.

Inomax can be used as a method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide, a method of providing a predetermined concentration of nitric oxide to a patient, a method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient, a method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide, a method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient, a method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient.

The generics of Inomax are possible to be released after 03 November, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846112 MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Jun, 2029

(6 years from now)

US8282966 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Jun, 2029

(6 years from now)

US8293284 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Jun, 2029

(6 years from now)

US8431163 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Jun, 2029

(6 years from now)

US8795741 MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Jun, 2029

(6 years from now)

US8282966

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Dec, 2029

(6 years from now)

US8293284

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Dec, 2029

(6 years from now)

US8431163

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Dec, 2029

(6 years from now)

US8795741

(Pediatric)

MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Dec, 2029

(6 years from now)

US8846112

(Pediatric)

MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Dec, 2029

(6 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US8573209 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8776795 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US9295802 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Feb, 2034

(11 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Aug, 2034

(11 years from now)

US9770570 MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
May, 2036

(13 years from now)

US9770570

(Pediatric)

MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
Nov, 2036

(13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing a predetermined concentration of nitric oxide to a patient; A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in